Evidence map›Paper›PMID 39168874›Full record

ArticleEuropean journal of clinical pharmacology2024

Prognostic effect of a vasopressin V

Kenichi Matsushita, Kazumasa Harada, Takamichi Miyamoto, Kiyoshi Iida, Yoshiya Yamamoto, Yasuyuki Shiraishi, Yuji Nagatomo, Hideaki Yoshino, Takeshi Yamamoto, Ken Nagao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenichi MatsushitaTokyo CCU Network Scientific Committee, Tokyo, Japan. kenichi-matsushita@umin.ac.jp.
Kazumasa HaradaTokyo CCU Network Scientific Committee, Tokyo, Japan.
Takamichi MiyamotoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Kiyoshi IidaTokyo CCU Network Scientific Committee, Tokyo, Japan.
Yoshiya YamamotoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Yasuyuki ShiraishiTokyo CCU Network Scientific Committee, Tokyo, Japan.
Yuji NagatomoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Hideaki YoshinoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Takeshi YamamotoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Ken NagaoTokyo CCU Network Scientific Committee, Tokyo, Japan.
Morimasa TakayamaTokyo CCU Network Scientific Committee, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science KAKENHI 17K09523 and 21K08109
6 · The paper itself

Abstract

purposeThis study investigated whether the oral vasopressin V

methodsData on 5511 consecutive CHF patients were extracted from the Tokyo CCU Network data registry. Congestion and hypoperfusion were defined by Nohria-Stevenson clinical profiles at the time of hospitalization. Propensity scores for tolvaptan use were calculated for each patient and used to assemble two matched cohorts of patients receiving tolvaptan or not in the CHF with and without hypoperfusion groups.

resultsOf the entire study cohort, 1073 patients (19%) had CHF with hypoperfusion (i.e. the wet-cold pattern). In-hospital mortality was significantly higher for CHF patients with than without hypoperfusion (log-rank, P < 0.001). The rate of tolvaptan use did not differ significantly between CHF patients with and without hypoperfusion (15% vs. 14%, respectively; P = 0.7848). In the propensity-matched CHF with hypoperfusion cohort, there was a significant association between the use of tolvaptan and a reduction in in-hospital mortality (log-rank, P = 0.0052). Conversely, in the matched CHF without hypoperfusion cohort, tolvaptan use was not associated with in-hospital mortality (log-rank, P = 0.4417).

conclusionThere was a significant association between the use of tolvaptan and a reduction in in-hospital mortality in CHF patients with, but not without, hypoperfusion. These findings hint at possible individualized therapies for patients with CHF.

Indexed as

Antidiuretic Hormone Receptor AntagonistsHeart FailureTolvaptanAgedAged, 80 and overFemaleHospital MortalityHumansMaleMiddle AgedPrognosisReceptors, VasopressinRegistriesAntidiuretic Hormone Receptor AntagonistsReceptors, VasopressinTolvaptanCardiorenal syndromeCongestive heart failureDiureticsMortalityTolvaptan

Identifiers

PMID39168874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.